Julie’s advice: Conducting oncology clinical research in Canada
Julie's advice: Conducting oncology clinical research in Canada Include Canada early in your drug development planning! Building relationships with key…
Clinical Trial Agreements no longer a bottleneck for study site activation
Ending the clinical trial agreement's sabotage of clinical trial startup Clinical trials are inherently complex, from pre-study startup through to…
‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 2
Continued from ‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiation part 1 Nathan Currier, PhD, is Scimega's…
Oncology Clinical Operations in Canada
The nature and structure of our health care system in Canada results in patients being followed at the same center…
‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 1
Nathan Currier, PhD, is Scimega's Director of Oncology Strategy and Alliances. He brings a wealth of knowledge and excellent insight…
Accelerate Start-up for Oncology Clinical Trials through Centralized Ethics Review
The strong demand for optimised oncology clinical trials has led Canadian provinces to implement centralised ethics review. Granted many of these provincial ethics…
Proven Approach to Site Selection is Attracting More Cutting-Edge Oncology Trials to Canada
12 Early-Phase Oncology Programs Started-Up in Canada Over Last 18-Months
Scimega Oncology, (www.scimega.com) the company behind the revolutionary Reverse Feasibility Program, announced it has been awarded
Impact of Clinical Trials on Cancer Patient Outcomes
Those of us who work in clinical operations and oncology drug development can sometimes get caught up in the operations or science and lose sight of the impact our work can have on the lives of people battling cancer. I’d like to share one man’s story to illustrate
Leveraging Canada For Quicker Oncology Site Start-Up
A biotech sponsor in the United States had targeted July 2015 for completion of enrollment for a Phase I dose-finding HER2+BrCa study.
How to Start-Up 9 Oncology Sites in 9 weeks
Over the last decade, increased competition for finite patient populations in the U.S. have led many drug developers to expand…